Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–140 of 140 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined oral contraceptives Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

NCT01360996
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3 mg DRSP/20 μg EE
Drug
Lead sponsor
Woman's
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 9, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

NCT04333576
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix, Placebo, Combined Oral Contraceptive
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
176
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

NCT00656981
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
22
States / cities
Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 9, 2026, 6:14 AM EDT
Terminated Phase 4 Interventional Results available

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

NCT02531321
View directory record Official record
Conditions
Contraception, HIV
Interventions
Levonorgestrel and Ethinyl Estradiol
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive

NCT04423055
View directory record Official record
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Sacramento, California • Denver, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

NCT05579574
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

Metabolic Syndrome in PCOS: Precursors and Interventions

NCT00442689
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Metabolic Syndrome
Interventions
flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

NCT05891262
View directory record Official record
Conditions
Healthy Female Volunteers
Interventions
BMS-986196, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

NCT03984825
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Portia
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 9, 2026, 6:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

NCT07766369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

NCT01236768
View directory record Official record
Conditions
Contraception
Interventions
AG200-15, Levora
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Danicopan

NCT04709094
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

NCT06775730
View directory record Official record
Conditions
Healthy Adult Female Participants
Interventions
Ensitrelvir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 9, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

NCT01044498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 9, 2026, 6:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

NCT00682890
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Insulin Sensitivity
Interventions
placebo, metformin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 9, 2026, 6:14 AM EDT